Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial
Status:
Recruiting
Trial end date:
2026-01-01
Target enrollment:
Participant gender:
Summary
Compare the efficacy and safety of camrelizumab, apatinib plus FOLFOX-HAIC and camrelizumab
plus apatinib in hepatocellular carcinoma with portal vein invasion.